Silvia Lorenzotti
University of Brescia
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Silvia Lorenzotti.
American Journal of Infection Control | 2008
Angelo Pan; Francesca Domenighini; Liana Signorini; Renata Assini; Patrizia Catenazzi; Silvia Lorenzotti; Andrea Patroni; Giampiero Carosi; Gianbattista Guerrini
In an Italian long-term-care facility (LTCF), we observed a 17.5% adherence to hand hygiene (HH), as well as 47.5% rate of glove use. Performing a procedure at high risk for cross-transmission of germs was the factor most strongly associated with noncompliance (odds ratio = 13.3; 95% confidence interval = 6.2 to 28.8; P < .0001). No significant differences in compliance related to health care worker category were found. Adherence to HH in the LTCF was similar to that found in a rehabilitation medicine unit of an acute care hospital (15.8%) but significantly lower than that reported in an infectious disease unit (53.7%; P < .0001). Our findings indicate that compliance with HH is a similar problem in LTCFs as in acute care facilities.
Infection Control and Hospital Epidemiology | 2007
Angelo Pan; Placido Mondello; Klara M. Posfay-Barbe; Patrizia Catenazzi; Annise Grandi; Silvia Lorenzotti; Andrea Patroni; Nadia Poli; Laura Soavi; Giuseppe Carnevale
In an Italian hospital, we observed that hand hygiene was performed in 638 (19.6%) of 3,253 opportunities, whereas gloves were worn in 538 (44.2%) 1,218 of opportunities. We observed an inverse correlation between the intensity of care and the rate of hand hygiene compliance (R2=0.057; P<.001), but no such association was observed for the rate of glove use compliance (R2=0.014; P=.078). Rates of compliance with hand hygiene and glove use recommendations follow different behavioral patterns.
International Journal of Epidemiology | 2015
Carlo Torti; Elena Raffetti; Francesco Donato; Francesco Castelli; Franco Maggiolo; Gioacchino Angarano; Francesco Mazzotta; Andrea Gori; Laura Sighinolfi; Angelo Pan; Roberto Cauda; Alfredo Scalzini; Eugenia Quiros-Roldan; Paola Nasta; Giampietro Gregis; Simone Benatti; Simona Digiambenedetto; Nicoletta Ladisa; Mariarosaria Giralda; Annalisa Saracino; Filippo Castelnuovo; Massimo Di Pietro; Sergio Lo Caputo; Giuseppe Lapadula; Silvia Costarelli; Silvia Lorenzotti; Nicola Mazzini; Giuseppe Paraninfo; Salvatore Casari; Emanuele Focà
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort) Carlo Torti, Elena Raffetti,* Francesco Donato, Francesco Castelli, Franco Maggiolo, Gioacchino Angarano, Francesco Mazzotta, Andrea Gori, Laura Sighinolfi, Angelo Pan, Roberto Cauda, Alfredo Scalzini, Eugenia Quiros-Roldan, Paola Nasta, Giampietro Gregis, Simone Benatti, Simona Digiambenedetto, Nicoletta Ladisa, Mariarosaria Giralda, Annalisa Saracino, Filippo Castelnuovo, Massimo Di Pietro, Sergio Lo Caputo, Giuseppe Lapadula, Silvia Costarelli, Silvia Lorenzotti, Nicola Mazzini, Giuseppe Paraninfo, Salvatore Casari, Emanuele Focà, Chiara Pezzoli, Massimiliano Fabbiani, Laura Monno, Piera Pierotti, Claudio Ble, Sebastiano Leone, Maria Concetta Postorino, Chiara Fornabaio, Fabio Zacchi, Alessia Zoncada and Giampiero Carosi Unità di Malattie Infettive e Tropicali, Dipartimento di Scienze Mediche e Chirurgiche, Università Magna Grecia di Catanzaro, Catanzaro, Italia, Unità di Igiene, Epidemiologia e Sanità Pubblica, Università degli Studi di Brescia, Brescia, Italia, Divisione Universitaria di Malattie Infettive Spedali Civili di Brescia-Università degli Studi di Brescia, Brescia, Italia, Malattie Infettive Ospedale Papa Giovanni XXIII, Bergamo, Italia, Clinica di Malattie Infettive Policlinico di Bari, Bari, Italia, Malattie Infettive S.M. Annunziata, Firenze, Italia, Malattie Infettive Ospedale San Gerardo di Monza, Monza, Italia, Malattie Infettive Nuovo Polo Ospedaliero di Cona, Ferrara, Italia, Malattie Infettive Istituti Ospitalieri di Cremona, Cremona, Italia, Clinica di Malattie Infettive Policlinico A. Gemelli-Università Cattolica di Roma, Roma, Italia, Divisione Ospedaliera di Malattie Infettive Spedali Civili, Brescia, Italia and Fondazione Malattie Infettive e Salute Internazionale, Brescia, Italia
The Open Aids Journal | 2016
Maria Concetta Postorino; Eugenia Quiros-Roldan; Franco Maggiolo; Simona Di Giambenedetto; Nicoletta Ladisa; Giuseppe Lapadula; Silvia Lorenzotti; Laura Sighinolfi; Filippo Castelnuovo; Massimo Di Pietro; Daria Gotti; Nicola Mazzini; Carlo Torti
Background and Objectives: Renal toxicity due to tenofovir (TDF) has been largely described in patients with HIV infection. However, other antiretroviral drugs (such as atazanavir [ATV], especially when boosted by ritonavir, ATV/r) could perpetuate some degrees of renal impairment with or without TDF co-administration. Also, possible benefits of stopping TDF in patients without renal diseases is not well known. This study aimed at exploring evolution of renal function and lipid profile after switching from tenofovir/emtricitabine (TDF/FTC) to abacavir/lamivudine (ABC/3TC), maintaining the ATV/r component of the regimen. Methods: Patients in the Italian MASTER Cohort, who switched from TDF/FTC plus ATV/r to ABC/3TC plus ATV/r were included, provided that major renal diseases were not diagnosed before switching (i.e., baseline). Serum creatinine, estimated glomerular filtration rate (eGFR), total cholesterol, HDL and triglycerides were evaluated at baseline and at month 18 after switching. Results: 126 patients were selected (80% males). Patients were mostly Italians (92%). 79% had undetectable HIV-RNA and 44% were co-infected by HBV and/or HCV. Median age at switch was 47 years (IQR 43-55). A small but significant decrease in serum creatinine [from 1.06 mg/dl (SD: 0.3) to 0.94 mg/dl (SD: 0.2); p<0.001] with an improvement in eGFR [from 86.8 ml/min (SD: 33) to 96.4 ml/min (SD: 37); p<0.001] were observed in per protocol analysis at month 18. Also ITT analysis showed a decrease in mean serum creatinine [from 1.08 mg/dl (SD: 0.35) to 0.95 mg/dl (SD: 0.24); p<0.001] with an improvement in mean eGFR [from 86.9 ml/min/1.73m2 (SD: 24.11) to 95.8 ml/min/1.73m2 (SD: 19.99); p<0.001]. Total cholesterol increased [from 188 mg/dl (SD: 42) to 206 mg/dl (SD: 44); p<0.001] but also HDL increased as well [from 46 mg/dl (SD: 14) to 54 mg/dl (SD: 19); p=0.015]. An increase in triglycerides concentration was observed [from 162 mg/dl (SD: 144) to 214 mg/dl (SD: 109); p=0.027] in per protocol analysis. Also ITT analysis showed increases of both total cholesterol [from 187 mg/dl (SD: 43.69) to 203 mg/dl (SD: 44.10); p<0.001] and HDL fraction [from 46 mg/dl (SD: 15.49) to 52 mg/dl (SD: 17.13); p=0.002] at month 18. Conclusion: This analysis reports an improvement in eGFR and an increase in total cholesterol and HDL fraction at month 18 after switching to ABC/3TC plus ATV/r. Given the fact that renal function was not significantly affected at baseline, our findings may suggest the utility of a proactive switch from TDF to ABC, when otherwise indicated, in patients who cannot avoid using a nucleoside backbone.
Clinical Microbiology and Infection | 2015
Maria Concetta Postorino; Mattia Prosperi; Eugenia Quiros-Roldan; Franco Maggiolo; S. Di Giambenedetto; Annalisa Saracino; Silvia Costarelli; Silvia Lorenzotti; Laura Sighinolfi; M. Di Pietro; Carlo Torti
Randomized trials and observational cohorts reported higher rates of virological suppression after highly active antiretroviral therapy (HAART) including efavirenz (EFV), compared with boosted protease inhibitors (PIs). Correlations with immunological and clinical outcomes are unclear. Patients of the Italian MASTER cohort who started HAART from 2000 to 2010 were selected. Outstanding outcome (composite outcome for success (COS)) was introduced. We evaluated predictors of COS (no AIDS plus CD4+ count >500/mm(3)plus HIV-RNA <500 copies/mL) and of eight single outcomes either at month 6 or at year 3. Multivariable logistic regression was conducted. There were 6259 patients selected. Patients on EFV (43%) were younger, had greater CD4+ count, presented with AIDS less frequently, and more were Italians. At year 3, 90% of patients had HIV RNA <500 copies/mL, but only 41.4% were prescribed EFV, vs. 34.1% prescribed boosted PIs achieved COS (p <0.0001). At multivariable analysis, patients on lopinavir/ritonavir had an odds ratio of 0.70 for COS at year 3 (p <0.0001). Foreign origin and positive hepatitis C virus-Ab were independently associated with worse outcome (OR 0.54, p <0.0001 and OR 0.70, p 0.01, respectively). Patients on boosted PIs developed AIDS more frequently either at month 6 (13.8% vs. 7.6%, p <0.0001) or at year 3 (17.1% vs. 13.8%, p <0.0001). At year 3, deaths of patients starting EFV were 3%, vs. 5% on boosted PIs (p 0.008). In this study, naïve patients on EFV performed better than those on boosted PIs after adjustment for imbalances at baseline. Even when virological control is achieved, COS is relatively rare. Hepatitis C virus-positive patients and those of foreign origin are at risk of not obtaining COS.
Infection Control and Hospital Epidemiology | 2006
Angelo Pan; Silvia Lorenzotti; Lucio Ferrari; Rn Luisa Granata; Liana Signorini; Giuseppe Carnevale
International Journal of Antimicrobial Agents | 2006
Federico Pea; Mario Furlanut; Roberto Stellini; Stefano Bonardelli; Liana Signorini; Federica Pavan; Albert Matheis; Nazario Portolani; Silvia Lorenzotti; Stefano Maria Giulini; Pierluigi Viale; Giampiero Carosi
GIMPIOS | 2017
Nigritella Brianese; Alessia Zoncada; Andrea Patroni; Alice Ferraresi; Chiara Fornabaio; Paola Lanza; Silvia Lorenzotti; Ewelyn van Hauwermeiren; Fabio Zacchi; Carmine Tinelli; Nicola Pasquali; Massimo Rovatti; Mario Martinotti; Angelo Pan
GIMPIOS | 2013
Elda Benelli; Alessia Zoncada; Giuliana Mazzei; Lucio Ferrari; Silvia Lorenzotti; Giuseppina Maghini; Evelyn Van Hauwermeiren; Leonardo Galli; Angelo Pan
GIMPIOS | 2011
Angelo Pan; Enrico Bombana; Grazia Tura; Anna Maria Buono; Marina Busetti; Alessandra Calabrese; Paolina Cavalcanti; Caterina Cusano; Cesarina Curti; Patrizia Farruggia; Paolo Fazii; Concetta Francone; Luca Fabbri; Maurizio Fiorio; Silvia Lorenzotti; Patrizia Lobati; Lorena Martini; Placido Mondello; I. Mura; Paola Occelli; Gian Paolo Pagliari; Paolo Pellegrino; Andrea Patroni; Giampiero Pellizzer; Manuela Rosina; Liana Signorini; Evelina Tacconelli; Margherita Vizio; Vilma Rigobello